Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals, Inc. reports developments tied to its specialty pharmaceutical portfolio, research and development programs, and public-company governance. The company combines research and development, clinical, manufacturing, and commercial capabilities, with commercialized products including PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® in Japan, and BYFAVO® through Acacia Pharma Inc. Its pipeline is described around oncology and CNS/metabolic critical care product candidates.
Recurring Eagle news includes portfolio actions such as the U.S. Barhemsys marketing-authorization divestiture, availability of audited and unaudited financial statements, annual meeting materials and voting results, board and stockholder matters, and amendments to its limited-duration stockholder rights plan.
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced on January 14, 2026 the divestiture of the U.S. marketing authorization for Barhemsys (amisulpride) to LXO Group, Paris. Barhemsys, approved by the FDA in February 2020 and launched in the U.S. in November 2020, is described as the only FDA-approved treatment for postoperative nausea and vomiting (PONV). Eagle said cash proceeds will be used for ongoing business operations. LXO said it will deploy a direct hospital sales force for Barhemsys, aiming to create synergies with its U.S. portfolio and shared distribution channels.
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced that its Board amended and extended the company’s limited duration stockholder rights plan by one year to October 30, 2026, effective immediately.
The amendment was made in response to ongoing significant trading-price dislocation and increases the potential dilution an acquirer would face if the plan is triggered. Rights become exercisable if a person or group acquires ≥10% beneficial ownership (or ≥15% for passive institutional investors). Grandfathered holders above the thresholds remain at current levels but may not increase ownership without triggering the plan.
Each exercisable Right permits purchase for $20.00 of shares with a market value equal to twice that price; the Rights Plan will expire automatically on October 30, 2026 unless redeemed or exchanged earlier.
Eagle Pharmaceuticals (OTCMKTS: EGRX) reported results from its 2025 annual meeting held virtually on October 17, 2025. Of 13,157,754 shares outstanding, 10,769,820 shares (≈82%) were present or represented by proxy.
All four director nominees were elected: Class I nominees Michael Graves and Richard Edlin (terms to 2027), and Class II nominees Jennifer Simpson and Luciana Borio (terms to 2028). Broker non-votes totaled 1,064,408. The stockholder vote also ratified BDO USA, P.C. as auditor for fiscal 2025 (FOR 9,011,921; AGAINST 1,700,348; ABSTAIN 57,551).
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced on Oct 15, 2025 that its unaudited financial statements for the three and six months ended June 30, 2025 are available for investors.
The statements can be accessed via the company’s investor relations page at https://investor.eagleus.com/events-presentations.
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced that its unaudited financial statements for the three months ended March 31, 2025 are available online. The documents can be accessed at the company's investor events and presentations page for review by shareholders and analysts.
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced the availability of proxy materials for its upcoming 2025 Annual Meeting of Stockholders, scheduled for October 17, 2025 at 10:00 a.m. Eastern Time. The meeting will be held virtually.
Stockholders of record as of August 18, 2025 will receive a Notice of Internet Availability of Proxy Materials. All proxy materials, including the notice, proxy information statement, and proxy card, along with the company's audited financial statements for 2023 and 2024, can be accessed through www.proxyvote.com and the company's investor relations website.
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced the appointment of Abhinav "Abi" Jain as an independent member of its Board of Directors. Jain, an Analyst at Nantahala Capital Management which holds approximately 38% of Eagle's shares, will serve as a Class III director until the 2026 Annual Meeting and join the Compensation and Nominating committees.
As part of a cooperation agreement with Nantahala, Eagle has committed to appointing a second independent director by May 15, 2026. Jain brings experience from his roles at Nantahala and Angelo, Gordon & Co., with expertise in specialty and generic pharmaceuticals investments.
Eagle Pharmaceuticals (OTCMKTS: EGRX) has announced its 2025 Annual Meeting of Stockholders will be held on October 17, 2025. The company has set August 18, 2025 at 5 p.m. Eastern Time as the record date for stockholder participation. Specific details regarding the meeting time and location will be communicated directly to eligible stockholders through official meeting materials.
Eagle Pharmaceuticals (EGRX) has entered into a $69 million royalty purchase agreement with Blue Owl Capital to sell its royalty interest in BENDEKA® (bendamustine hydrochloride injection) U.S. sales. The transaction provides immediate, non-dilutive capital to Eagle.
Under the agreement, Eagle will receive the upfront payment in exchange for a prespecified royalty interest for Q4 2024 and 100% thereafter, up to 1.3x the purchase price. After reaching this cap, future royalty payments will revert to Eagle.
The company plans to use the proceeds to fully repay its Credit Agreement, including $27.5 million in term loan and $25 million in revolving credit facility. Remaining funds will support general corporate purposes, including ongoing R&D programs like CAL02 for severe community-acquired bacterial pneumonia and EA 114 for hormone-receptor-positive metastatic breast cancer.
Eagle Pharmaceuticals (EGRX) has announced an amendment to its duration stockholder rights plan, doubling the initial purchase price of preferred share purchase rights from $10.00 to $20.00. The Rights Plan targets any person or group that acquires 10% ownership (15% for passive institutional investors) of company stock without Board approval.
The amendment responds to significant stock price dislocation and aims to increase potential dilution for unauthorized acquirers. The plan's primary objectives are to protect long-term stockholder value and prevent control acquisition through open market accumulation without fair compensation. The Rights Plan will automatically expire on October 30, 2025, unless rights are redeemed or exchanged earlier.